Seroprevalence of Hepatitis-B Infection Amongst Taiwanese University Students 18 Years Following the Commencement of a National Hepatitis-B Vaccination Program
Overview
Affiliations
In Taiwan, the nation-wide Hepatitis-B virus (HB) vaccination program was first launched in July 1984 and was directed to those infants born to hepatitis B surface antigen (HBsAg) carrier mothers in Taiwan. From July 1986 onwards, all infants born in Taiwan were immunized against HB. This study examined the HB-infection status amongst students at a Taiwanese university 18 years subsequent to the implementation of universal HB vaccination. A total of 1,969 new university entrants in 2005 were grouped into 1 of 3 distinct birth cohorts according to their HB-vaccination schedule (cohort-1 students born prior to July 1, 1984; cohort-3 students born subsequent to June 30, 1986) and were examined for their serum HBsAg, antibody to hepatitis B surface antigen (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) status. Immunity arising from vaccination was defined as an anti-HBs level 10 mIU/ml. We observed a trend toward a decreasing anti-HBc-positive rate and a decreasing HBsAg carrier rate from, respectively, 26.5 and 8.7% for cohort-1 to 4.7 and 1.7% for cohort-3 students. The prevalence of students featuring seronegativity for all three HB markers increased from 12.3% for cohort-1 to 48.8% for cohort-3 individuals. Amongst the 1,695 subjects revealing seronegativity for HBsAg and anti-HBc, their anti-HBs level was analyzed according to their birth year. The prevalence of students featuring a non-protective anti-HBs level increased from 11.9% for birth-year 1984 individuals to 48.2% for birth-year 1987 students. The introduction of HB vaccine has effectively reduced the transmission of HBV infection in Taiwan, 18 years subsequent to the commencement of the universal HB-vaccination program. A "waning-off" effect of anti-HBs seropositivity acquired from the HB vaccination program has also been observed.
Li J, Gao Z, Bai H, Wang W, Li Y, Lian J BMC Public Health. 2024; 24(1):2936.
PMID: 39443929 PMC: 11515762. DOI: 10.1186/s12889-024-20462-4.
Salvadori N, Gauthier L, Guy M, Ngo-Giang-Huong N, Khamduang W, Decker L J Virus Erad. 2024; 9(4):100356.
PMID: 38161321 PMC: 10755356. DOI: 10.1016/j.jve.2023.100356.
Cheng T, Yang J, Chen Y, Wu K, Lee M, Kuo H Vaccines (Basel). 2023; 11(2).
PMID: 36851225 PMC: 9964940. DOI: 10.3390/vaccines11020348.
Wang H, Zhang J, Liu J, Jiang Y, Fu L, Peng S Front Mol Biosci. 2023; 10:1124956.
PMID: 36845547 PMC: 9947156. DOI: 10.3389/fmolb.2023.1124956.
Liu M, Li L, Zhao J, Ungvari G, Ng C, Duan Z PeerJ. 2022; 10:e13828.
PMID: 35959480 PMC: 9359133. DOI: 10.7717/peerj.13828.